Summary:

According to Pharmarack, India’s Pharmaceutical Market (IPM) grew by 7.2% in May 2025, driven by price increases and new product launches, despite a unit growth rate of just 0.4%. Chronic therapies such as cardiac and anti-infectives grew by 11.7% and 7.6%, respectively, while urology and antineoplastics expanded by 12.3% and 11.7%. Antidiabetics saw a 6.1% volume increase, supported by off-patent drugs and new combinations. From June 2024 to May 2025, the market’s moving annual turnover (MAT) rose by 8.1% to ₹2,29,000 crore (US$ 26.72 billion), with a 1.1% increase in volume. Companies such as Sun Pharma and Dr. Reddy’s reported 11.2% growth. The top-selling brands were GSK’s Augmentin and USV’s Glycomet GP, with sales of ₹819 crore and ₹810 crore, respectively.

Source: IBEF

Disclaimer:The information on this website comes from the India Brand Equity Foundation (IBEF), a reliable source for thorough insights into numerous areas of the Indian economy. While we aim to offer accurate and up-to-date information, the views, opinions, and analyses stated herein are solely those of the authors and contributors and do not necessarily represent IBEF's official stance or position. Readers should check information from credible sources and use their own discretion when relying on content provided on this site. We assume no responsibility or liability for the supplied content, including its accuracy, completeness, and usefulness.